Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Sparfloxacin" patented technology

Sparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. It has a controversial safety profile. It was patented in 1985 and approved for medical use in 1993. Zagam is no longer available in the United States.

Ureaplasma urealyticum/mycoplasma hominis combined rapid culture and drug sensitivity detection kit

Provided is a ureaplasma urealyticum/mycoplasma hominis combined rapid culture and drug sensitivity detection kit. The kit can complete detection in 8-24 h, and meanwhile, drug-resistant detection of various antibiotics can be performed. The combined rapid culture kit is mainly composed of pork stomach digestive juice or lung digestive juice, a beef extracting solution or a beef heart extracting solution, cattle serum or horse serum or other animal serum, sodium chloride, peptone, yeast powder, urea, L-arginine, phenol red indicator or cresol red indicator, and penicillin or other antibiotics. The drug detection kit can detect doxycycline hyclate, roxithromycin, acetylspiramycin, gatifloxacin, clarithromycin, azithromycin, clindamycin, erythromycin, kitasamycin, ofloxacin, levofloxacin hydrochloride, sparfloxacin, ciprofloxacin, doxycycline, erythromycin cydocarbonate and various other antibiotics. By means of the detection kit, not only is the mycoplasma detection time shortened, but also drug-resistant detection can be performed at the same time so that clinical medication can be guided. The detection kit has the beneficial effects of being high in sensitivity, high in specificity, high in detection rate, easy and convenient to operate and the like.
Owner:姜洪波 +1

New application of quinolone compounds in prevention and treatment of plant bacterial diseases such as citrus canker

The invention discloses a new application of quinolone compounds as bactericides in prevention and treatment of bacterial diseases and citrus canker of crops. The quinolone compounds comprise floroxacin, enofloxacin, gatifloxacin, moxifloxacin hydrochloride, enrofloxacin, marbofloxacin, floxacin, mononorfloxacin mesylate, prulifloxacin, Balofloxacin, pazufloxacin mesylate, pipemidic acid, sparfloxacin, difloxacin hydrochloride, lomefloxacin hydrochloride, pefloxacin, tosufloxacin mesylate, Cinoxacin, galafloxacin, besifloxacin hydrochloride, ofloxacin, nalidixic acid, Clinafloxacin and Sitafloxacin. The quinolone compounds can be used for preventing and treating bacterial diseases caused by citrus canker pathogens, especially gatifloxacin, moxifloxacin hydrochloride, mononorfloxacin mesylate, sparfloxacin, tosufloxacin mesylate, clinafloxacin and sitafloxacin, has excellent bacteriostatic activity on citrus canker pathogens, and can be used for preventing and treating bacterial diseases of crops.
Owner:LANZHOU UNIVERSITY

Fructose injection of antibiotic medicine

The invention relates to fructose injection of an antibiotic medicine. The fructose injection of the antibiotic medicine consists of antibiotics, fructose and water and also comprises proper additives, wherein the antibiotics comprise gatifloxacin, levofloxacin, ciprofloxacin, pazufloxacin, fleroxacin, sparfloxacin, moxifloxacin, pefloxacin, rufloxacin, lomefloxacin, norfloxacin, caderofloxacin, azithromycin, telithromycin, ornidazole, secnidazole, tinidazole, metronidazole, clindamycin, lincomycin, fluconazole, etimicin, netilmicin, amikacin as well as medicinal acid addition salt, esterification compounds, derivatives and the like; the fructose injection is prepared from the antibiotics; the advantages that the injection is convenient to use and takes effect rapidly are achieved; and compared with the glucose injection, the fructose injection is easier to absorb and utilize, more suitable for antisepsis and anti-inflammation, energy supply and body liquid supplementation of patientssuffering from diabetes, heart diseases and liver diseases, and enlarges the use range.
Owner:WEIHAI HAOTONG MEDICAL SCI & TECH

Medicinal preparation for resisting intracellular mycoplasma infection and application thereof

The invention discloses a medicinal preparation for resisting intracellular mycoplasma infection and an application thereof, and belongs to the technical field of medicines. The pharmaceutical preparation is a sparfloxacin solution with the final concentration of 10 mg / ml, is obtained by dissolving sparfloxacin in a 0.1 mol / l NaOH solution and sequentially filtering through a 0.45 [mu]m filter and a 0.22 mu m filter, is used for preventing cells from infecting mycoplasma and removing the mycoplasma infecting the cells during cell culture, and is continuously used for 7 days every 1-2 days according to the effective use dosage of 0.01-0.1 mg sparfloxacin / ml cell culture medium. The sparfloxacin active compound is dissolved in the NaOH solution to prepare the solution preparation by adopting an alkali solution dissolution method, the solution preparation can replace mycillin to be used for preventing cells from infecting mycoplasmas and removing the mycoplasmas infecting the cells during cell culture, the antibacterial effect is good, toxicity and drug resistance are low, damage to the cells is small while the mycoplasmas are effectively killed, and the mycoplasma can be prevented from polluting the cells again.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Polypyrrole/cadmium sulfide imprinted composite photocatalyst as well as preparation method and application thereof

The invention discloses a polypyrrole / cadmium sulfide imprinted composite photocatalyst which comprises a crystalline cadmium sulfide photocatalyst serving as a carrier and a polypyrrole imprinted layer formed on the surface of the carrier. The polypyrrole imprinted layer is internally provided with holes formed by taking sparfloxacin as template molecules. The invention also discloses a preparation method and application of the photocatalyst, and a method for degrading sparfloxacin. The polypyrrole / cadmium sulfide imprinted composite photocatalyst provided by the invention has strong stability and can selectively and effectively degrade sparfloxacin.
Owner:SHENZHEN POLYTECHNIC

Slow released capsule of sparfloxacin and bletilla tuber glue for animal and birds

The present invention belongs to the field of veterinary medicine technology, and is especially slow released veterinary medicine capsule prepared with sparfloxacin and bletilla tuber as material. The preparation process includes the following steps: water extracting and alcohol precipitation to extract bletilla tuber glue; mixing sparfloxacin and bletilla tuber in the ratio of 1 to 3 and 10 % concentration alcohol solution of PVP as adhesive; making pellet of 20 meshes and encapsulating. The slow released veterinary medicine capsule has long medicine retaining time in the disease focus, high local medicine concentration, excellent bioadhesion and obvious medicine slow releasing characteristic.
Owner:TIANJIN RINGPU BIO TECH

Preparation method of slow-release sparfloxacin injection

The invention provides a preparation method of a slow-release sparfloxacin injection and relates to a slow-release injection for animals. The sparfloxacin injection comprises components in percentage by weight as follows: 5%-20% of sparfloxacin, 1%-4% of fatty acid, 5%-35% of a stabilizer and the balance of an organic solvent. The sparfloxacin and the organic solvent are taken and stirred to be dissolved, the fatty acid is added to have a complex reaction with a dissolution product, the stabilizer is added and fully dissolved, the organic solvent is added until the mixture reaches a certain volume and is subjected to membrane filtration, and the slow-release sparfloxacin injection is prepared. New composition is formed after sparfloxacin, salt of sparfloxacin or hydrate of sparfloxacin has a reaction with the fatty acid, the release time of sparfloxacin can be prolonged, the effective blood concentration of the medicine in the animals is maintained for a long time, and accordingly, the purposes of reducing administration frequency and stress due to the medicine are achieved.
Owner:TIANJIN RINGPU BIO TECH

Organic composite photocatalyst for degrading drugs and pathogenic bacteria and preparation method thereof

The invention discloses an organic composite photocatalyst for degrading drugs and pathogenic bacteria and a preparation method of the organic composite photocatalyst, and belongs to the technical field of treatment of pollutants in water. According to the method disclosed by the invention, the loaded photocatalyst is obtained by loading the cephalosporin onto the macroporous adsorption resin through a simple green method. The photocatalyst can generate singlet oxygen, superoxide free radicals and the like even under the irradiation of sunlight and a fluorescent lamp. The oxygen free radicals can react with drugs and pathogenic bacteria, so that the purpose of degrading the drugs and the pathogenic bacteria is achieved. According to the method, the drugs can be completely degraded within 3 hours under illumination, and the drugs comprise antibacterial drugs such as quinolone ciprofloxacin, gatifloxacin, moxifloxacin, ofloxacin, enrofloxacin and sparfloxacin, sulfonamide trimethoprim and antiviral drugs such as chloroquine phosphate. In addition, the photocatalyst can effectively inhibit pathogenic bacteria staphylococcus aureus, and simultaneous removal of drugs and pathogenic bacteria in water pollution is achieved.
Owner:JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products